Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
WAT
HoldPremium GrowerFLAGWaters Corporation · Healthcare · United States · $40.7B · Avg Vol: $302M/d
Insufficient evidence for a screen-pass. Waters Corporation: fails the quant gate on value (Q64/V22/M71; every leg must be >= 50). Absence of evidence is neutral; nothing adverse is known.
COMPANY DESCRIPTION
Waters Corporation develops and manufactures analytical laboratory instruments, software, and services for liquid chromatography, mass spectrometry, and thermal analysis, serving pharmaceutical, life science, and industrial research. It is a market leader in high-performance liquid chromatography (HPLC) and mass spectrometry, benefiting from a deeply embedded installed base, proprietary technologies, and high customer switching costs. Waters is a critical enabler of scientific research and quality control across diverse industries.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.0B | 3.0B | 3.0B | 3.2B | 2.1% | 4.6B | 6.5B | 7.1B | 50.1% |
| EPS | 11.80 | 10.87 | 10.75 | 10.80 | -2.9% | 3.93 | 11.99 | 13.61 | 12.3% |
| Shares | 59.1M | 59.2M | 59.4M | 59.5M | +0.8% | — | — | — | — |
| Debt | 1.7B | 2.4B | 1.7B | 1.5B | -3.6% | 5.5B | — | — | — |
| Equity | 504.5M | 1.2B | 1.8B | 2.6B | 71.9% | — | — | — | — |
| Op CF | 611.7M | 602.8M | 762.1M | 652.6M | 2.2% | 549.6M | — | — | — |
| Inv CF | -108.0M | -1.4B | -143.1M | -152.3M | — | — | — | — | — |
| Fin CF | -509.6M | 755.0M | -696.7M | -237.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of WAT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| WAT | Waters Corporation(you) | $40.7B | 62 | Hold |
| IDXX | IDEXX Laboratories, Inc. | $43.7B | 58 | Hold |
| NTRA | Natera, Inc. | $47.0B | 56 | Hold |
| IQV | IQVIA Holdings Inc. | $43.1B | 73 | Buy |
| A | Agilent Technologies, Inc. | $43.4B | 75 | Buy |
| ILMN | Illumina, Inc. | $32.6B | 75 | Buy |
| CRL | Charles River Laboratories International, Inc. | $14.0B | 63 | Hold |
| RVTY | Revvity, Inc. | $14.4B | 64 | Hold |
| DGX | Quest Diagnostics Incorporated | $26.8B | 82 | Strong Buy |
| DHR | Danaher Corporation | $151.9B | 59 | Hold |
Peer medians: ROE -30.7% · P/E 26.9x · Gross margin 58.3%